“Paul knows the cath lab market as well as anyone,” said Gonzague Issenmann, Stentys’ co-founder and chief executive officer. “He was the head of the interventional cardiology department at University Hospital Antwerp at the start of his professional career, and combined with his extensive business experience over more than two decades, Paul is an outstanding addition to our management team.”

“Paul joins Stentys on the heels of the Company’s CE Mark approval for its disconnectable and self-expanding platform, and he will lead Stentys’ commercial development in this $2.5 billion market,” added Jacques Séguin, M.D., Ph.D., co-founder and Chairman of Stentys and founder of CoreValve.